FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890257481> ?p ?o ?g. }

• W2890257481 endingPage "4125" @default.
• W2890257481 startingPage "4125" @default.
• W2890257481 abstract "4125 Background: Pancreatic cancer (PC) is a challenging target for immunotherapy.Tumor-infiltrating lymphocytes (TILs) do not reach the PC cells in significant numbers due to the presence of stroma and a suppressive microenvironment. Neoadjuvant chemoradiation (CRT) can increase the presence of TILs in the PC microenvironment. We hypothesized that combination of CRT and pembrolizumab can lead to further increase in TILs and their activation. Methods: Patients with resectable or borderline resectable PC have been randomized 2:1 to the investigational treatment (Arm A) to receive pembrolizumab 200mg IV every 3 weeks on days 1, 22, and 43 during concurrent CRT with capecitabine (825 mg/m2 orally twice daily, Monday-Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days) or Arm B to receive only concurrent CRT with capecitabine. Restaging CT scan or MRI is performed at 4-6 weeks after completion of neoadjuvant treatment, and patients with resectable disease will undergo surgical resection. Here we report the preliminary safety data based on 22 enrolled patients. Results: As of February 3-2017,22 patients have been enrolled (14 Arm A and 8 Arm B). 50% of the patients had resectable disease (7 arm A; 4 arm B) and the other 50% had borderline resectable disease (7 Arm A; 4 arm B). Post-neoadjuvant therapy, 6 patients had unresectable disease (3 on each arm), and 14 patients underwent surgery (10 arm A and 4 arm B). There were 7 grade 3 treatment-related toxicities in Arm A (5 patients): 2 grade 3 diarrhea attributed to CRT; 4 grade 3 lymphopenias attributed to pembrolizumab, CRT or the combination; and one patient had elevated alkaline phosphatase probably related to the combination that met the definition of DLT and resolved after holding the treatment and receiving steroids. There was only one grade 3 toxicity on Arm B: lymphopenia attributed to CRT. No grade 4 toxicities have been reported on either arm. There were no major surgical complications reported within 30 days post-surgery. Conclusions: The combination of CRT and pembrolizuamb is safe based on the presented data. Clinical trial information: NCT02305186." @default.
• W2890257481 created "2018-09-27" @default.
• W2890257481 creator A5003827387 @default.
• W2890257481 creator A5004999918 @default.
• W2890257481 creator A5011254389 @default.
• W2890257481 creator A5012936802 @default.
• W2890257481 creator A5016606073 @default.
• W2890257481 creator A5021842242 @default.
• W2890257481 creator A5038925117 @default.
• W2890257481 creator A5054771911 @default.
• W2890257481 creator A5056639411 @default.
• W2890257481 creator A5077902939 @default.
• W2890257481 creator A5080783554 @default.
• W2890257481 creator A5088853428 @default.
• W2890257481 creator A5090865977 @default.
• W2890257481 date "2017-05-20" @default.
• W2890257481 modified "2023-10-18" @default.
• W2890257481 title "Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer." @default.
• W2890257481 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4125" @default.
• W2890257481 hasPublicationYear "2017" @default.
• W2890257481 type Work @default.
• W2890257481 sameAs 2890257481 @default.
• W2890257481 citedByCount "10" @default.
• W2890257481 countsByYear W28902574812019 @default.
• W2890257481 countsByYear W28902574812020 @default.
• W2890257481 countsByYear W28902574812021 @default.
• W2890257481 countsByYear W28902574812022 @default.
• W2890257481 crossrefType "journal-article" @default.
• W2890257481 hasAuthorship W2890257481A5003827387 @default.
• W2890257481 hasAuthorship W2890257481A5004999918 @default.
• W2890257481 hasAuthorship W2890257481A5011254389 @default.
• W2890257481 hasAuthorship W2890257481A5012936802 @default.
• W2890257481 hasAuthorship W2890257481A5016606073 @default.
• W2890257481 hasAuthorship W2890257481A5021842242 @default.
• W2890257481 hasAuthorship W2890257481A5038925117 @default.
• W2890257481 hasAuthorship W2890257481A5054771911 @default.
• W2890257481 hasAuthorship W2890257481A5056639411 @default.
• W2890257481 hasAuthorship W2890257481A5077902939 @default.
• W2890257481 hasAuthorship W2890257481A5080783554 @default.
• W2890257481 hasAuthorship W2890257481A5088853428 @default.
• W2890257481 hasAuthorship W2890257481A5090865977 @default.
• W2890257481 hasConcept C121608353 @default.
• W2890257481 hasConcept C126322002 @default.
• W2890257481 hasConcept C141071460 @default.
• W2890257481 hasConcept C143998085 @default.
• W2890257481 hasConcept C2777701055 @default.
• W2890257481 hasConcept C2777909004 @default.
• W2890257481 hasConcept C2778292576 @default.
• W2890257481 hasConcept C2780057760 @default.
• W2890257481 hasConcept C2780210213 @default.
• W2890257481 hasConcept C509974204 @default.
• W2890257481 hasConcept C526805850 @default.
• W2890257481 hasConcept C530470458 @default.
• W2890257481 hasConcept C71924100 @default.
• W2890257481 hasConceptScore W2890257481C121608353 @default.
• W2890257481 hasConceptScore W2890257481C126322002 @default.
• W2890257481 hasConceptScore W2890257481C141071460 @default.
• W2890257481 hasConceptScore W2890257481C143998085 @default.
• W2890257481 hasConceptScore W2890257481C2777701055 @default.
• W2890257481 hasConceptScore W2890257481C2777909004 @default.
• W2890257481 hasConceptScore W2890257481C2778292576 @default.
• W2890257481 hasConceptScore W2890257481C2780057760 @default.
• W2890257481 hasConceptScore W2890257481C2780210213 @default.
• W2890257481 hasConceptScore W2890257481C509974204 @default.
• W2890257481 hasConceptScore W2890257481C526805850 @default.
• W2890257481 hasConceptScore W2890257481C530470458 @default.
• W2890257481 hasConceptScore W2890257481C71924100 @default.
• W2890257481 hasIssue "15_suppl" @default.
• W2890257481 hasLocation W28902574811 @default.
• W2890257481 hasOpenAccess W2890257481 @default.
• W2890257481 hasPrimaryLocation W28902574811 @default.
• W2890257481 hasRelatedWork W1978895290 @default.
• W2890257481 hasRelatedWork W2002928668 @default.
• W2890257481 hasRelatedWork W2032042555 @default.
• W2890257481 hasRelatedWork W2939195303 @default.
• W2890257481 hasRelatedWork W3009875009 @default.
• W2890257481 hasRelatedWork W3021135223 @default.
• W2890257481 hasRelatedWork W4240544598 @default.
• W2890257481 hasRelatedWork W4248193205 @default.
• W2890257481 hasRelatedWork W4292255383 @default.
• W2890257481 hasRelatedWork W4317567212 @default.
• W2890257481 hasVolume "35" @default.
• W2890257481 isParatext "false" @default.
• W2890257481 isRetracted "false" @default.
• W2890257481 magId "2890257481" @default.
• W2890257481 workType "article" @default.